Histological effects and predictive biomarkers of TPP induction chemotherapy for oral carcinoma.
The effects of an induction chemotherapy with THP-adriamycin, cisplatin, and peplomycin (TPP) were studied in 32 patients with operable oral cancer. The histological evaluation according to the Shimozato-Oboshi classification was Grade (G) IV in ten cases (31.3%), GIII in one case, and GIIb in four cases. Induction of apoptosis and differentiation-inducing effects, hyperkeratinization or bone formation, were observed in some cases. The overall clinical response rate and histological response rate were 63% and 47%, respectively. Grade III was obtained in seven metastatic lymph nodes of three patients. The expressions of PCNA, p53, and AgNORs before and after chemotherapy were studied. The prechemotherapeutic PCNA positive cell index (PI) of the highly responsive tumors (GIII, IV) was significantly lower than that of the poorly responsive tumors (G0-IIb) (P < 0.01). Similar results were obtained in the evaluation of p53 PI (P < 0.05), suggesting that PCNA and p53 are useful biomarkers for predicting the efficacy of TPP chemotherapy.
Hamakawa
H
H
Department of Oral and Maxillofacial Surgery, Ehime University School of Medicine, Japan.
Bao
Y
Y
Takarada
M
M
Tanioka
H
H
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D014408:Biomarkers, Tumor / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002454:Cell Differentiation / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage*; D004396:Coloring Agents; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D005544:Forecasting; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D007633:Keratins / Q000187:drug effects; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D009697:Nucleolus Organizer Region / Q000187:drug effects / Q000648:ultrastructure; D010012:Osteogenesis / Q000187:drug effects; D017663:Peplomycin / Q000008:administration & dosage*; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis / Q000235:genetics; D012074:Remission Induction; D012834:Silver; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000235:genetics
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004396:Coloring Agents; D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53; D012834:Silver; D017663:Peplomycin; D007633:Keratins; D004317:Doxorubicin; C027260:pirarubicin; D002945:Cisplatin